Pharmaceuticals Companies By Ebitda
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
EBITDA
EBITDA | Efficiency | Market Risk | Exp Return | ||||
---|---|---|---|---|---|---|---|
1 | MRK | Merck Company | 0.04 | 1.89 | 0.07 | ||
2 | JNJ | Johnson Johnson | 0.12 | 1.31 | 0.16 | ||
3 | PFE | Pfizer Inc | 0.08 | 1.46 | 0.12 | ||
4 | AZN | AstraZeneca PLC ADR | 0.07 | 1.65 | 0.11 | ||
5 | LLY | Eli Lilly and | 0.00 | 1.95 | 0.00 | ||
6 | ZTS | Zoetis Inc | (0.05) | 1.63 | (0.09) | ||
7 | BMY | Bristol Myers Squibb | (0.01) | 1.92 | (0.02) | ||
8 | VTRS | Viatris | 0.05 | 2.08 | 0.11 | ||
9 | BHC | Bausch Health Companies | 0.13 | 2.88 | 0.37 | ||
10 | ELAN | Elanco Animal Health | 0.14 | 1.94 | 0.27 | ||
11 | COLL | Collegium Pharmaceutical | 0.14 | 1.73 | 0.24 | ||
12 | AMPH | Amphastar P | (0.09) | 2.11 | (0.19) | ||
13 | HRMY | Harmony Biosciences Holdings | 0.04 | 2.07 | 0.09 | ||
14 | SUPN | Supernus Pharmaceuticals | 0.20 | 1.63 | 0.32 | ||
15 | ANIP | ANI Pharmaceuticals | (0.04) | 2.11 | (0.09) | ||
16 | ACB | Aurora Cannabis | 0.03 | 4.45 | 0.11 | ||
17 | PCRX | Pacira BioSciences, | (0.07) | 2.16 | (0.16) | ||
18 | HROW | Harrow Health | 0.16 | 3.61 | 0.56 | ||
19 | HCM | HUTCHMED DRC | 0.13 | 2.86 | 0.38 | ||
20 | CPIX | Cumberland Pharmaceuticals | 0.03 | 8.87 | 0.23 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital. In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.